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Abstract
BACKGROUND: Splenic inflammatory pseudotumor (IPT)/inflammatory myofibroblastic tumor (IMT) is a rare 
pseudotumor/tumor of unknown origin, which is usually benign, although atypical and aggressive cases have been 
reported. It is a lesion composed of proliferated myofibroblastic cells (hence IMT by some authors) with admixed 
pleomorphic inflammatory cells of varying proportions. 
CASE REPORT: Herein, we report a case of 61-year-old male patient with ill-defined abdominal discomfort and no 
other symptoms and signs. Clinical and imaging investigations revealed a mass in the spleen that was equivocally 
interpreted as secondary neoplasm, although primary neoplasm of the spleen was not excluded by the radiologists. 
Splenectomy was performed and on gross examination a well demarcated greyish-livid tumor measuring 3.5 cm 
× 3 cm × 3 cm was discovered. Microscopic examination showed proliferation of loosely arranged spindle cells 
admixed with inflammatory cells (histiocytes, lymphocytes, neutrophils, eosinophils, occasional plasma cells, and/
or plasmacytoid cells) with varying density and multifocal clustering, multifocal hemorrhage, and fibrinoid-like 
deposition. We performed additional histochemical and immunohistochemical stainings which were consistent with 
the diagnosis of IPT/IMT. Next-generation sequencing (TruSight Tumor 15) showed common TP53 polymorphism 
(c.215C>G; p.Pro72Arg) along with several intronic and synonymous single nucleotide variations (SNVs), as well as 
five low confidence missense SNVs. Sixteen months after the operation the patient has uneventful follow-up.
CONCLUSION: Although the incidence of IPT/IMT is low, awareness of its existence is necessary. The prognosis 
is favorable following splenectomy in most cases. Careful microscopic examination of the specimen is mandatory, 
due to possible misdiagnosis. We believe that extensive NGS analysis on archive samples would provide more data 
about the spectrum of possible genetic changes in lesions like IPM/IMT.
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Introduction
Inflammatory pseudotumor (IPT) of the spleen is 
an extremely rare tumor-like lesion with approximately <115 
published cases in adults until 2015, and probably not more 
than 116 cases until year 2017, at the best of our knowledge 
[1], [2], [3], [4], [5], [6]. This entity was first introduced in 
1984 by Cotelingam and Jaffe [1]. It is a lesion composed of 
proliferated spindle cells with admixed inflammatory cellular 
component of variable composition including lymphocytes, 
plasma cells, histiocytes, and granulocytes [1], [2], [3], [4], 
[5], [6]. Additional studies have demonstrated that spindle 
cells are in fact myofibroblasts, prompting the designation 
inflammatory myofibroblastic tumor (IMT) [2]. More recent 
studies have challenged the still controversial view that 
IPT and IMT are the same entity [7]. IPT is notorious for 
mimicking malignant neoplasm of the spleen, while its 
etiology and pathogenesis are not fully understood. IPT 
is more frequently found in other locations including orbit, 
digestive system, spinal meninges, soft tissues, bladder, 
liver, lymph nodes, and with lungs being a predilection site 
affected in age ranges from pediatric to elderly patients 
over 60, both males and females [6], [8], [9]. Although the 
pathogenesis is not fully understood, associations have been 
reported with bacterial and viral (Epstein-Barr virus [EBV], 
and human herpesvirus 8) infections, some immunological 
derangements, neoplastic processes, previous surgery, 
ventriculoperitoneal shunt, trauma, radiation therapy, and 
steroid usage [2], [3], [4], [5], [6], [7]. Contradicting views 
have been published about the relationship between EBV 
infection and occurrence of IPT, additionally linking the IPT 
to IMT, frequently used as a synonym according to some of 
the authors [4], [8], [10], [11], [12]. Besides publications that 
approximate IPT and IMT, or use the terms interchangeably 
[7], there are authors that oppose this view, stating that IPT 
of lymph nodes and spleen is biologically different from IMT 
[10], [11]. The main arguments for this distinction probably 
come from the findings that IMTs are more frequently 
associated with EBV infection, and approximately 50% 
of them harbor anaplastic lymphoma kinase 1 (ALK1) 
rearrangements or activating mutations in one of three 
other receptor tyrosine kinases including ROS1, RET, and 
neurotrophic tyrosine receptor kinase 3 [7], [10], [11], [12]. 
Cases with aggressive behavior of IPT/IMT have been 
reported, either with local recurrences or even metastatic 
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spread [2], [3], [4], [7], [8], [10], [11], [12], [13]. Although 
exceedingly rare, IMT may arise in the breast also [14], [15], 
posing a special differential diagnostic challenge, taking 
into consideration the broad range of other fibroblastic/
myofibroblastic breast proliferations such as fibromatosis, 
pseudoangiomatous stromal hyperplasia, nodular fasciitis, 
myofibroblastoma, and possibly phyllodes tumor with 
stromal overgrowth, which although rare in absolute 
numbers, comprise the majority of mesenchymal spindle 
cell lesions of the breast [16].
Case Report
A 61-year-old male was admitted at the University 
Clinic for Abdominal Surgery for splenectomy. One month 
before, he was incidentally diagnosed with splenic tumor 
during routine US examination for ill-defined abdominal 
discomfort. Computed tomography (CT) scan showed focal, 
42 mm in diameter, hypodense lesion with peripheral post-
contrast signal, which was interpreted as secondary neoplasm 
by the radiologist. However, primary splenic neoplasm was 
not excluded in the differential diagnosis. On admittance, the 
patient had no specific complaints and no symptoms or signs 
of interest, except for productive cough. CT scan of the thorax 
was negative, as well as gastric and colonic endoscopy. 
Laboratory findings were as follows: Conjugated bilirubin 
slightly elevated at 7.25 µmol/L (Ref. up to 6,8), globulins 
25.1 g/L (Ref. 27–35), and tumor markers (CA 72-4, CEA, CA 
19-9, CA125) were negative; hemogram, coagulation status, 
enzymes (alanine transaminase, aspartate transaminase, 
alkaline phosphatase, and alpha-amylase), and C-reactive 
protein and metabolites (blood urea nitrogen, and creatinine) 
were within reference ranges. The patient’s history contained 
nothing of interest for the present condition.
Macroscopic presentation
Removed spleen weighted 225 g and measured 
11 9.5 cm × 4.5 cm. On cut surfaces, a well demarcated 
solid, greyish-livid tumor measuring 3.5 cm × 3 cm × 
3 cm, with bulging surface, appeared. The surrounding 
splenic tissue was unremarkable (Figure 1).
Figure 1: Cut surface of the spleen
Microscopic findings
The tumor mass was composed of loosely 
arranged, elongated oval and plump spindle cells 
admixed with pleomorphic inflammatory cells 
(histiocytes, lymphocytes, neutrophils, eosinophils, 
occasional plasma cells, and/or plasmacytoid cells) 
with varying density and multifocal clustering. There 
was multifocal deposition of fibrinoid-like material in the 
stroma in fascicular and net-like fashion. Throughout 
the lesion, there were dilated thin-walled and larger 
blood vessels with multifocal hemorrhage (Figure 2).
Figure 2: Microphotographs of the splenic lesion. H and E staining. (a) 
Well demarcated tumor border from the surrounding splenic tissue. (b) 
Variable cellularity within the lesion. (c) Loosely arranged spindle cells 
with admixed inflammatory cells including lymphocytes, histiosites, 
plasma cells, several eosinophils, and neutrophils. (d) Focal fibrinoid-like 
deposition, (e) focus of hemorrhage, (f) white pulp follicle with expanded 
marginal zone in otherwise unremarkable surrounding splenic tissue
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Immunohistochemical stainings for CD3, CD20, 
CD68, CD138, kappa, and lambda immunoglobulin light 
chains, highlighted the cellular composition and distribution 
of the inflammatory cells within the lesion as well as in the 
surrounding splenic tissue. The smooth-muscle actin and 
S-100A4 revealed diffuse proliferation of myofibroblastic 
cells with variable density within the lesion. The proliferation 
index (Ki-67) was lower than 5% (Figure 3).
Figure 3: Microphotographs of immunohistochemical staining (EnVision flex; 
DAKO) depicting cellular composition, relative relations, and distribution. (a) T 
lymphocyte clusters within the lesion (CD3 staining; ×40). (b) B-lymphocytes 
(CD20 staining; ×100) (c) number of histiocytes diffusely distributed (CD68 
staining; ×40) (d and e) kappa and lambda light immunoglobulin chains 
showing polyclonal pattern of immunohistochemical expression (Kappa; 
Lambda stain; ×40) (f) diffuse positivity for smooth muscle actin (stain; ×40) 
(g) low proliferation index (<5%) (Ki-67 staining; ×40)
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The crystal violet and Ziehl–Neelsen stains 
were negative, as well as EBV and ALK1 immunostains 
(not shown). Surrounding splenic tissue showed 
focal marginal zone expansion in some of the white 
pulp follicles and increased intrafollicular T-cell influx 
(Figure 4).
Figure 4: Microphotographs of immunohistochemical stainings 
(EnVision flex; DAKO) for B and T lymphocytes in the white pulp 
of the peritumoral splenic tissue. (a) B-lymphocytes in the reactive 
lymphoid follicle with expanded marginal zone (CD20 staining; ×40). 
(b) Increased T-lymphocyte influx in some of the reactive lymphoid 
follicles (CD3 staining; ×40)
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Epstein–Barr encoded RNA test was not 
performed because of low RNA quality. Tumor DNA was 
subjected to next-generation sequencing using 15 genes 
panel covering: AKT1, BRAF, EGFR, ERBB2, FOXL2, 
GNA11, GNAQ, KIT, KRAS, MET, NRAS, PDGFRA, 
PIK3CA, RET, and TP53 (TruSight Tumor 15 panel 
on Miseq DX; Illumina). Next-generation sequencing 
(NGS) revealed homozygous TP53 polymorphism 
(c.215C>G; p.Pro72Arg), besides several intronic and 
synonymous variations with no clinical significance, as 
well as five low confidence missense single nucleotide 
variations (SNVs) (Table 1).
Table 1: Next-generation sequencing: TruSight tumor 15 
missense single nucleotide variations (low confidence)
Gene transcript Exon c.DNA
prot. 
alteration
Variant fraction 
coverage 
(ref/alt)
Pathogenicity ClinVar
AKT1
NM_001014431
3 c.73C>T
p.(Arg25Cys)
1.19%
(13728/165 )
Prediction: 
Highly 
pathogenic
Pathogenic
rs397514644
ERBB2
NM_001005862
21 c.2024C>T
p.(Ala675Val)
1.26%
(4392/56)
Prediction: 
Potentially 
Pathogenic
ERBB2
NM_001005862
20 c.1957C>T
p.(Arg653Trp)
1.09%
(3815/42)
Prediction: 
Potentially 
pathogenic
ERBB2
NM_001005862
20 c.1972C>T
p.(Arg658Trp)
1.49%
(3758/57)
Prediction: 
Potentially 
pathogenic
TP53
NM_000546
8 c.917G>A
p.(Arg306Gln)
1.3%
(6458/85)
Prediction: 
Potentially 
pathogenic
Our diagnosis was IPT/IMT of spleen. During 
the follow-up, 16 months after the operation the patient 
has had an uneventful recovery.
Discussion
Splenic IPT/IMT is a rare pseudotumor/
tumor of unknown origin, which is usually benign, 
although atypical and aggressive cases have been 
reported [2], [3], [4], [7], [8], [10], [11], [12], [13]. 
According to the available literature probably not more 
than 116 cases with splenic localization have been 
reported in adults, and more commonly in women. 
Clinically, it is often associated with fever of unknown 
origin and splenomegaly, may present with B symptoms 
including weight loss, fever, and abdominal pain, but 
may be an incidental finding as well [2]. The actual 
pathogenesis is unknown, although possible factors 
include bacterial infection, neoplastic processes, 
and immunological derangements with some cases 
being associated with EBV infection. Associations 
have been also reported with the previous surgery, 
ventriculoperitoneal shunt, trauma, radiation therapy, 
and steroid usage [2], [3], [4], [5], [6], [7]. None of these 
conditions have been identified in our patient during 
the diagnostic process, and none have additionally 
appeared 16 months after the surgery. Acknowledging 
that IPT and IMT lay in the spectrum of the same entity, 
the differential diagnosis includes splenic hamartoma, 
follicular dendritic cell tumor, and mycobacterial infection 
in immunocompromised patients [2], [3], [7]. Splenic 
hamartomas are tumor-like masses of disorganized 
but mature tissue indigenous to the spleen and is 
composed exclusively of red pulp elements, lacking 
follicles, or fibrous trabeculae [2], [3], [4]. Unlike IPT/
IMT, follicular dendritic cell tumor is smooth muscle 
actin negative, but CD21 and CD35 positive, ruling 
it out in our case [2], [3]. Mycobacterial infection in 
immunocompromised patients usually presents with 
nodules in the red pulp made up of CD68+ spindle 
cells which contain acid-fast bacilli in their cytoplasm. 
In our case, no acid-fast bacilli were identified, and 
the patient also did not present any other signs of 
immunodeficiency. In general, speaking, in cases where 
similar lesion is located outside the spleen or lymph 
nodes, a broader spectrum of differential diagnoses 
comes into play, including fibromatosis, nodular fasciitis, 
pseudoangiomatous stromal hyperplasia of the breast, 
myofibroblastoma, and phyllodes tumor with stromal 
overgrowth in breast, as well as entities like cranial 
fasciitis of childhood in cases where pediatric patients 
are involved [7], [9], [11], [13], [14], [15], [16], [17]. All 
of the previously mentioned entities are composed 
of proliferating spindle mesenchymal cells with 
varying site-specific clinical presentations and varying 
immunophenotypic features of the spindle fibroblastic/
myofibroblastic cells regarding the differential 
expression patterns of SMA, S-100, β-catenin, HER2, 
estrogen, and progesterone receptors [16], which helps 
distinguish them from each other and from IPT/IMT as 
well, besides the fact that most of them (in typical cases) 
lack the mixed inflammatory substrate characteristic for 
IPT/IMT.
However, in case IPT and IMT are accepted 
as separate entities, than excluding one of them 
would probably be additional challenge in each similar 
case. As far as distinction between IPT and IMT is 
concerned, according to the several authors including 
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Gleason and Hornick and Kutok et al., and Coffin et 
al., IPT of lymph nodes and spleen is a non-neoplastic 
entity distinct from IMT, with most of the patients 
being adults [7], [10], [11]. On the other hand, unlike 
cases with nodal localization who frequently present 
systemic symptoms and laboratory abnormalities 
seen in a minority of IMT patients, splenic IPTs are 
often asymptomatic, and rarely associated with nodal 
lesions and vice versa, raising the possibility that 
even these two entities may be unrelated, despite 
histological similarity [7]. The analysis of the NGS data 
in our case revealed only the c.215C>G; p.Pro72Arg 
TP53 polymorphism as reliable finding, besides few 
more intronic and synonymous variations with no 
clinical significance. Low confidence SNVs detected in 
our patient (Table 1) were not considered as a reliable 
finding during the diagnostic process due to the low 
variant fraction coverage, but initiated an idea that if 
a reactive pseudotumors lesion was undergoing early 
steps of oncogenesis where certain fraction of cells 
was put under selective pressure for survival, it would 
be understandable that some of these cells would 
try to escape death by increasing survival signaling, 
thus possibly acquiring errors in some components 
of the affected signaling pathways, in our case AKT1, 
ERBB2, and TP53. Taking into consideration, the 
small fraction of cells that would normally escape the 
selective pressure by undergoing this initial oncogenic 
steps compared to the bulk of the cells in the lesion, 
suddenly the “low confidence” SNVs (<2% variant 
fraction) acquire new meaning, especially the highly 
pathogenic c.73C>T (p.Arg25Cys) SNV in the AKT1 
gene. In the further development, these changes could 
provide selective advantage of this small fraction of 
cells leading to formation of a true neoplastic lesion 
featuring specific cell cycle derangements. In our 
opinion activation of tyrosine kinases [12] or other 
genetic variations that could be categorized as driver 
mutations, would favor true neoplasm (e.g. IMT) over 
reactive lesion like IPT, as defined originally. This could 
be a criterion for distinguishing cases of IPT versus 
IMT with the latter being a real tumor with specific 
genetic abnormalities. Although the incidence of IPT/
IMT is low, awareness of its existence is necessary, 
since its occurrence can sometimes lead to serious 
complications and may pose a diagnostic problem. 
The prognosis is favorable following splenectomy in 
most cases, although recurrences and even metastatic 
disease have been reported [7], [8], [10], [11], [12], [13]. 
Careful microscopic examination of the specimen is 
mandatory, due to possible misdiagnosis. We believe 
that extensive NGS analysis on archive samples would 
provide more data about the spectrum of possible 
genetic changes in these lesions, and subsequent 
correlation with the outcome may elucidate the issue 
of distinction between IPT and IMT. Such analyses 
would be further beneficial for establishing thresholds 
(regarding variant fraction coverage) for selecting 
significant NGS findings in lesions like IPM/IMT.
Conclusion
Although the incidence of IPT/IMT is low, 
awareness of its existence is necessary. The prognosis 
is favorable following splenectomy in most cases. 
Careful microscopic examination of the specimen is 
mandatory, due to possible misdiagnosis. We believe 
that extensive NGS analysis on archive samples would 
provide more data about the spectrum of possible 
genetic changes in lesions like IPM/IMT.
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